BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cronexitide lanocianine readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Cronexitide lanocianine\, from ClinicalTr
 ials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07276789-2599@assetmemo.bio
DTSTAMP:20261121T005939Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Cronexitide lanocianine: Phase 2 readout est. (NCT07276789)
DESCRIPTION:Cronexitide lanocianine\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence
  Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cance
 r Resection for Non Small Cell Lung Cancer\nEstimated primary completion: 
 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cronexitid
 e-lanocianine#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07276789
URL:https://assetmemo.bio/drug/cronexitide-lanocianine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
